California

Vivo Capital

Vivo Capital, based in California, backs healthtech and life sciences companies at Series A and B, mostly following other investors, with $6.1B in active AUM.

Entry stageSeries A, Series B
Check sizen/a
Leads roundsMostly follows
FocusHealthtech, Life sciences
Latest fund$6.1B active AUM (Q4 2025)
Investing team19 peopleNo activity since Sep

Who you would pitch at Vivo Capital

19 people on the investing team, 8 of them partners who can make the call. Partners are listed first.

Chen MengManaging DirectorHe previously held leadership roles at New Frontier Group and a sovereign fund in Asia.
Frank KungManaging PartnerHe previously held leadership roles at Cetus Immune Corporation and Genelabs Technologies, Inc.
Gaurav AggarwalManaging PartnerHe has over twenty years of experience investing in the life sciences sector.
Hao DongManaging DirectorHe has a background in investment banking and entrepreneurship.
Michael ChangManaging PartnerHe has a professional background in healthcare strategy and operations.
Shan FuManaging Partner
David LiuPartnerHe previously held leadership roles in process research and development at several pharmaceutical companies.
Kevin DaiPartnerHe has a background in clinical oncology pharmacy and equity research.
Allison YanPrincipalShe previously worked at Ernst & Young and holds an M.A. in Accounting from North Carolina State University.
Andrew HuangPrincipalHis background is not detailed in the excerpts.
Gilles NkanaPrincipalHe previously worked at Alta Semper Capital and Goldman Sachs, and holds an M.B.A. from Columbia Business School.
Jiawei LiuPrincipalHe previously worked at Boston Consulting Group as a management consultant in the healthcare industry.
Lingfei ZhaoPrincipal, PIMShe completed internships at BNP Paribas and Blackstone Group during her studies.
Linus TanPrincipal
Mike LuPrincipal
Pierre YouPrincipal, PIM
Xiaoyang LiPrincipalShe holds degrees from Imperial College London and Stanford University.
Michael ChanAnalystHe previously served as a Part-time Fellow at Columbia Technology Ventures and as a Graduate Researcher at Columbia University.
Richard DingAnalystHe previously worked at Shine Asset Management focusing on biopharmaceuticals and computational biology, and holds degrees from Cornell University…

Work here and something is wrong? Ask for a correction.

Check size not reported yet.

Bars: how many firms in the atlas report each band. Highlighted: this firm.

No recent activity since September 2026. Quiet does not mean closed.

Weekly count of activity updates. Activity is not a confirmed deal.

Before you pitch

How to reach them[email protected]

Notable investments

Ascendis PharmaZai LabCompass PathwaysPrecision BioSciencesWuXi PharmaTech (WuXi AppTec)Sierra OncologySilence TherapeuticsTarsus Pharmaceuticals
Founders and investors at a Mode VC gathering

Send Mode VC your deck

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.

Send your deck

Alert me when Vivo Capital is active

One email when this firm shows new activity. Nothing else.

Firms like Vivo Capital

On these lists

Questions

What stage does Vivo Capital invest in?

Vivo Capital reports entry at series a, series b.

How much does Vivo Capital invest?

Vivo Capital has not reported a check size.

Does Vivo Capital lead rounds?

Vivo Capital mostly follows other investors.

Who are the partners at Vivo Capital?

Chen Meng (Managing Director), Frank Kung (Managing Partner), Gaurav Aggarwal (Managing Partner), Hao Dong (Managing Director), Michael Chang (Managing Partner), Shan Fu (Managing Partner).

Is Vivo Capital active right now?

No recent activity since September 2026.

Work at Vivo Capital? Claim or correct this profile.